History | Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 148 KB)

Published:

26 October 2022
Register of interests (PDF 416 KB)

Published:

26 October 2022

Final draft guidance

Final appraisal document (PDF 237 KB)

Published:

23 September 2022
Committee papers (PDF 4.14 MB)

Published:

23 September 2022
Public committee slides (PDF 1.37 MB)

Published:

23 September 2022

Invitation to participate

Equality impact assessment (Scoping) (PDF 129 KB)

Published:

29 November 2021
Draft scope and provisional stakeholder list comments table (post-referral) (PDF 171 KB)

Published:

29 November 2021
Final scope (PDF 193 KB)

Published:

29 November 2021
Final stakeholder list (PDF 188 KB)

Published:

29 November 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Draft scope post referral (PDF 205 KB)

Published:

08 September 2021
Draft matrix post referral (PDF 185 KB)

Published:

08 September 2021